Scientific Research and Publications

Neos ADHD Medication Bibliography

Amphetamine Extended-Release Orally-Disintegrating Tablets

Publications

  1. Stark JG, Engelking D, McMahen R, Sikes C. A randomized crossover study to assess the pharmacokinetics of a novel amphetamine extended-release orally disintegrating tablet in healthy adults. Postgrad Med. 2016;128(7):648-655.
  2. Stark JG, Engelking D, McMahen R, Sikes C. Pharmacokinetics of a novel amphetamine extended-release orally disintegrating tablet in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2017;27(3):216-222.
  3. Newcorn J, Stark JG, Adcock S, McMahen R, Sikes C. A randomized phase I study to assess the effect of alcohol on the pharmacokinetics of an extended-release orally disintegrating tablet formulation of amphetamine in healthy adults. Clin Ther. 2017;39(8):1695-1705.

Presentations

  1. Stark JG, McMahen R, Tengler M, Sikes C. Pharmacokinetic study of a novel extended-release formulation of amphetamine oral-disintegrating tablet in children aged 6–12 years with attention-deficit/hyperactivity disorder (ADHD). Poster presented at: The 60th American Academy of Child & Adolescent Psychiatry Annual Meeting; October 24, 2013; Orlando, FL.
  2. Stark JG, McMahen R, Tengler M, Sikes C. Oral bioavailability/bioequivalence of a novel investigational extended-release oral disintegrating tablet formulation of amphetamine for ADHD. Poster presented at: The 60th American Academy of Child & Adolescent Psychiatry Annual Meeting; October 24, 2013; Orlando, FL.
  3. Adcock S, Stark JG, McMahen R, Tengler M, Sikes C. The controlled-release properties and exposure levels of a novel orally disintegrating tablet formulation of amphetamine for treatment of ADHD are maintained in the presence of alcohol. Poster presented at: The American Society of Clinical Psychopharmacology Annual Meeting 2015; June 22-25, 2015; Miami, FL.
  4. Sikes C, Adcock S, Stark JG, McMahen R, Tengler M, Newcorn J. Alcohol does not alter the pharmacokinetics and plasma concentrations of a novel extended-release orally disintegrating tablet formulation of amphetamine for treatment of ADHD. Poster presented at: The 2016 Meeting of the American Professional Society of ADHD and Related Disorders; January 15-17, 2016; Washington, DC.
  5. Engelking D, Adcock S, Stark JG, McMahen R, Newcorn J, Sikes C. Alcohol does not alter the pharmacokinetics and plasma concentrations of a novel extended-release orally disintegrating tablet formulation of amphetamine for treatment of ADHD. Poster presented at: The American Association of Nurse Practitioners 2016 National Conference; June 21-26, 2016; San Antonio, TX.
  6. McMahen R, Stark JG, Engelking D, Sikes C. Pharmacokinetics of a novel extended-release orally disintegrating tablet amphetamine formulation under fed and fasted conditions. Poster presented at: The 63rd Annual Meeting of the American Academy of Child and Adolescent Psychiatry; October 24, 2016; New York, NY.

Methylphenidate Extended-Release Orally-Disintegrating Tablets

Publications

  1. Childress A, Newcorn J, Stark JG, McMahen R, Tengler M, Sikes C. A single-dose, single-period pharmacokinetic assessment of an extended-release orally disintegrating tablet of methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2016;26(6):505-512.
  2. Childress A, Kollins SH, Cutler AJ, Marraffino A, Sikes C. Efficacy, safety, and tolerability of an extended-release orally disintegrating methylphenidate tablet in children 6–12 years of age with attention-deficit/hyperactivity disorder in the laboratory classroom setting. J Child Adolesc Psychopharmacol. 2017;27(1):66-74.
  3. Childress A, Stark JG, McMahen R, Engelking D, Sikes C. A comparison of the pharmacokinetics of methylphenidate extended-release orally disintegrating tablets with a reference extended-release formulation of methylphenidate in healthy adults [published online ahead of print May 25, 2017]. Clin Pharmacol Drug Dev. doi:10.1002/cpdd.362.
  4. Weisler RH, Stark JG, Sikes C. Fed and fasted administration of a novel extended-release methylphenidate orally disintegrating tablet formulation for the treatment of ADHD [published online ahead of print May 25, 2017]. Clin Pharmacol Drug Dev. doi:10.1002/cpdd.361.

Presentations

  1. Tengler M, McMahen R, Stark JG, Sikes C. Pharmacokinetics of novel methylphenidate extended-release oral disintegrating tablets for ADHD. Poster presented at: The American Society of Clinical Psychopharmacology Annual Meeting 2015; June 22-25, 2015; Miami, FL.
  2. McMahen R, Tengler M, Stark JG, Sikes C. No food effect for a novel oral disintegrating tablet formulation of extended-release methylphenidate for the treatment of ADHD. Poster presented at: The American Society of Clinical Psychopharmacology Annual Meeting 2015; June 22-25, 2015; Miami, FL.
  3. Childress A, Stark JG, McMahen R, Tengler M, Sikes C. The pharmacokinetic properties of a novel extended-release oral disintegrating tablet formulation of methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder. Poster presented at: The 62nd American Academy of Child & Adolescent Psychiatry Annual Meeting; October 26-31, 2015; San Antonio, TX.
  4. Childress A, Kollins SH, Cutler AJ, Marraffino A, Sikes C. A new formulation of methylphenidate: phase 3 study of the efficacy and tolerability of an extended-release orally disintegrating tablet in children 6–12 years of age with ADHD. Poster presented at: The 62nd American Academy of Child & Adolescent Psychiatry Annual Meeting; October 26-31, 2015; San Antonio, TX.
  5. Tengler M, McMahen R, Stark JG, Childress A, Engelking D, Sikes C. Pharmacokinetics of a novel methylphenidate extended-release orally disintegrating tablet formulation. Poster presented at: The 2016 Meeting of the American Professional Society of ADHD and Related Disorders; January 15-17, 2016; Washington, DC.

Extended-Release Amphetamine Oral Suspension

Presentations

  1. Sikes C, Stark JG, McMahen R, Engelking D. Pharmacokinetics of a novel amphetamine extended-release oral suspension in children with attention-deficit/hyperactivity disorder. Poster presented at: The 2017 Annual Meeting of the American Professional Society of ADHD and Related Disorders; January 13-15, 2017; Washington, DC.

Other Neos-Supported Publication Activities

Presentations

  1. Childress A. Patients’ with ADHD and healthcare professionals’ perspectives on available ADHD formulations, swallowing tablets and capsules, and treatment adherence. Poster presented at: The 2016 Meeting of the American Professional Society of ADHD and Related Disorders; January 15-17, 2016; Washington, DC.
  2. Kehner G. Patients’ with ADHD and healthcare professionals’ perspectives on available ADHD formulations, swallowing tablets and capsules, and treatment adherence. Poster presented at: The American Association of Nurse Practitioners 2016 National Conference; June 21-26, 2016; San Antonio, TX.